Please login to the form below
Natpara
This page shows the latest Natpara news and features for those working in and with pharma, biotech and healthcare.
Shire finally bags EU approval for rare disease drug Natpar
US. Natpar - which is sold as Natpara in the US - has been given a conditional approval by the European Medicines Agency and becomes the first and only licenced recombinant human parathyroid ... Sales of Natpara in the US were $85m last year, which was a
Latest news
-
J&J gets CHMP backing for broader Darzalex use
ahead for Natpara (parathyroid hormone), a treatment for patients with chronic hypoparathyroidism who cannot be adequately controlled with standard treatment with calcium and vitamin D.
-
Rare disease therapies head the ‘class of 2015’
HDAC inhibitor. Novartis. USA. parathyroid hormone (recombinant). Natpara. hypocalcaemia in hypoparathyroidism.
-
Baxalta agrees to $32bn Shire takeover
drugs such as its HAE therapy Cinryze (C1 esterase inhibitor) and Natpara (recombinant parathyroid hormone) for hypoparathyroidism.
-
Shire deal with Baxalta predicted this week
HAE) therapy DX-2930 - and a $5.2bn purchase of NPS Pharma which gave it control of Natpara (recombinant parathyroid hormone) for hypoparathyroidism.
-
Shire makes shock $30bn bid for Baxalta
This came several months after the firm agreed to buy NPS for $5.2bn, gaining access to its lead product Natpara (recombinant parathyroid hormone) to treat low blood calcium levels in
More from news
Approximately 3 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
According to Bloomberg, the products Xiidra eyedrops for dry eye and Natpara for hypoparathyroidism may be considered as a source of funds to reduce the debt Takeda will incur in the
-
Pharma deals during January 2015
Interestingly, the offer was made by Shire ahead of the decision by the FDA on Natpara for hyperparathyroidism.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- VR/AR Applications for Training and Healthcare
PMHub
Mednet Group
PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
